Abstract:Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic malignancies. To date, the etiology of this deadly disease remains elusive. FHL2, a member of the four and a half LIM domain family, has been shown to serve either as an oncoprotein or as a tumor suppressor in various cancers. Our previous study showed that FHL2 plays a critical role in the initiation and progression of ovarian granulosa cell tumor via regulating AKT1 transcription. However, direct and systematic evidence of FHL2 in the initiation and progression of EOC remains unclear. In the present study, immunohistochemical analysis from EOC patient tissues showed that positivity and intensity of FHL2 immunosignal were up-regulated in the EOC tissues compared with normal ovary tissues. Knockdown of FHL2 in SKOV-3 cell line reduced cell growth and cell viability, blocked cell cycle progression, and inhibited cell migration. Ectopic expression of FHL2 in IGROV-1 cells which have low endogenous FHL2, promoted cell growth, improved cell viability and enhanced cell migration. Additionally, knock down of FHL2 in the SKOV-3 cell line significantly inhibited anchorage-independent growth indicated by the soft agar assay. In comparison, overexpression of FHL2 in IGROV-1 cell improved the colonies growth in soft agar. Western blot data showed that knockdown of FHL2 downregulated AKT expression level, and upregulated apoptosis related proteins such as cleaved PARP, and cleaved-lamin A. Finally, by employing stable SKOV-3/FHL2 stable knock down cell line, our data clearly showed that knockdown of FHL2 inhibited EOC xenograft initiation in vivo. Taken together, our results showed that FHL2, via regulating cell proliferation, cell cycle, and adhesion, has a critical role in regulating EOC initiation and progression. These results indicate that FHL2 could be a potential target for the therapeutic drugs against EOC.

The Four-and-a-half-lim Protein 2 (FHL2) is Overexpressed in Gliomas and Associated with Oncogenic Activities.

FHL Family and Tumor

The Four and a Half LIM Domains 2 (FHL2) Regulates Ovarian Granulosa Cell Tumor Progression Via Controlling AKT1 Transcription

Four and a Half LIM Domains Protein 1 Can Be As a Double-Edged Sword in Cancer Progression

Four-and-a-half LIM Protein 2 Promotes Invasive Potential and Epithelial-Mesenchymal Transition in Colon Cancer.

Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.

FHL2 protein:research advances

CSIG-19. FHL2 INTERACTS WITH EGFRVIII TO PROMOTE GLIOBLASTOMA GROWTH

Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-β–like signaling pathway

Four and a Half LIM Domains 2 Contributes to the Development of Human Tongue Squamous Cell Carcinoma

Four and a Half LIM Domains 2 (FHL2) Contribute to the Epithelial Ovarian Cancer Carcinogenesis

Role of four and a half LIM domain protein 1 in tumors (Review)

Oncogene Functions of FHL2 Are Independent from NF-κBIα in Gastrointestinal Cancer

Suppression of FHL2 Expression Induces Cell Differentiation and Inhibits Gastric and Colon Carcinogenesis

Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell.

Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling

Four and a Half LIM Protein 2 (FHL2) Negatively Regulates the Transcription of E-cadherin Through Interaction with Snail1.

Fhl1 Interacts With Oestrogen Receptors And Regulates Breast Cancer Cell Growth

Downregulation And Growth Inhibitory Role Of Fhl1 In Lung Cancer

The role of FHL1 in tumors

FHL1 Inhibits the Growth of Tongue Squamous Cell Carcinoma Cells Via G1/S Cell Cycle Arrest.